NewsSource: EClinCloud official website historical archive

EClinCloud eCOA System Passes CFDI Inspection, Supporting Marketing Approval of Raynovent's COVID-19 Treatment Leritrelvir Tablets

4 min readEClinCloud Editorial Team
Archived article cover: EClinCloud eCOA system passes CFDI inspection, supporting marketing approval of Raynovent's COVID-19 treatment leritrelvir tablets

The following article is from the "E-Pharma Manager" (E药经理人) WeChat Official Account

 

On 3/23/2023, the National Medical Products Administration (NMPA), in accordance with the relevant provisions of the Drug Administration Law and under the special drug approval procedure, granted conditional approval to Guangdong Raynovent Biotech Co., Ltd. (hereinafter referred to as "Raynovent") for its application to market the Category 1 innovative drug leritrelvir tablets (brand name: Leruiling). This drug is an oral small-molecule therapeutic for novel coronavirus infection, used to treat adult patients with mild-to-moderate novel coronavirus infection (COVID-19).

 

国家药监局来瑞特韦片批准信息  

 

Leritrelvir tablets act on the novel coronavirus (SARS-CoV-2) 3CL protease, inhibiting cleavage of the viral polyprotein precursor and thereby blocking viral replication to achieve an antiviral effect against SARS-CoV-2. In cell models infected with various SARS-CoV-2 strains, such as wild-type, Alpha, Beta, Delta, and Omicron (including BA.5 and BF.7), leritrelvir tablets can effectively inhibit SARS-CoV-2 replication, demonstrating broad-spectrum anti-SARS-CoV-2 activity.

 

In the Phase III clinical study supporting approval, EClinCloud leveraged its advanced eCOA system and the services of its professional medical and technical teams to develop an optimal data collection plan based on the clinical trial protocol, train investigators and other clinical study personnel, and transform traditional data collection methods. Through the eCOA system, EClinCloud collected evidence supporting efficacy and safety, provided technical support services and compliance guidance throughout the study, helped the sponsor obtain more complete clinical endpoint data in a timely manner, ensured data authenticity and validity, and supported the efficient and smooth conduct of the study.

 

Mr. Li Haijun, Senior Vice President of Raynovent, said: "The conditional marketing approval of leritrelvir tablets this time would not have been possible without the great care, guidance, and support of government departments and leaders at all levels for our company across all stages of drug R&D, nor without the full cooperation and dedicated support of all our partners. In the Phase III clinical study, we were fortunate to use the EClinCloud eCOA system, replacing the traditional paper diary cards used previously by collecting patient data electronically, which ensured data authenticity, timeliness, and traceability, reduced manual entry and verification steps, and greatly improved R&D efficiency. The EClinCloud team assisted throughout CFDI's on-site inspection; through the eCOA system, Raynovent's medical team was able to reconstruct the entire process for this portion of key data, earning recognition from the NMPA inspection experts. In the future, Raynovent will also make greater use of digital approaches to support clinical research and make greater contributions to global health."

 

Dr. Qin Long, Chief Executive Officer of EClinCloud, said: "As a technology company providing a SaaS cloud platform supporting clinical evidence, the EClinCloud team begins with the end in mind and draws on medicine and science to help sponsors obtain more reliable clinical trial endpoint data. Leritrelvir tablets is the fastest-approved program among the many Phase III clinical studies supported by EClinCloud, and we extend our sincere best wishes to Raynovent for bringing benefits to patients in China. EClinCloud will remain committed to using technological innovation to help bring more new drugs to market and benefit countless patients."

 

 

About Raynovent

 

Raynovent, based on its understanding and insights into the pathophysiology of respiratory and metabolic diseases, focuses on developing novel therapies for major diseases and public health challenges including influenza, COVID-19, avian influenza, idiopathic pulmonary fibrosis, non-alcoholic steatohepatitis, type 2 diabetes, and weight management. Raynovent has established multiple first-in-class or best-in-class drug development pipelines at various stages of development; China's first single-agent 3CL inhibitor, leritrelvir tablets, has received conditional marketing approval, and China's first innovative drug approved for clinical trials to treat NASH, ZSP1601, and the first RNA polymerase inhibitor for the treatment and prevention of influenza A and human avian influenza, ZSP1273, have entered Phase II and Phase III clinical trials, respectively.

 

 

About EClinCloud

 

EClinCloud is a technology company focused on clinical research and development, providing an integrated, interconnected all-in-one clinical trial cloud platform (including CTMS, eTMF, EDC, RTSM, and eCOA, among other technology products, as well as solutions such as scale management, linguistic validation, rater training, and data quality analysis) and clinical trial endpoint assessment technologies across diverse therapeutic areas (including oncology, central nervous system, ophthalmology, and others). Combining cutting-edge technology with life data, it builds a globally leading "patient-centric" SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency and accelerate the market launch of drugs/devices to benefit countless patients.

Related reading

Archived article cover: With Rising Pharmaceutical Submissions and Tightening Investment, How Can Digital Solutions Help Clinical Research Reduce Costs and Improve Efficiency?News7 min readWith Rising Drug Filings and Tightening Investment, How Can Digital Solutions Help Reduce Costs and Improve Efficiency in Clinical Research?As the biopharmaceutical industry continues to develop, innovative drug R&D has entered a period of rapid growth, and the number of clinical drug trials is trending upward. Alongside this, improving clinical trial efficiency and reducing the costs and risks of clinical research have become urgent priorities for a growing number of pharmaceutical companies and research institutions. Using digital tools to advance the digital and intelligent development of clinical trials is undeniably the prevailing trend. To better meet the needs of digital and intelligent clinical development and share the latest achievements and solutions, EClinCloud recently convened in Chengdu its first User Conference, "Digital and Intelligent Empowerment: Symbiosis and Win-Win," bringing together pharmaceutical industry leaders for discussions.Article cover for "Scale scoring: a different score from every rater? An overview of the history of neuropsychological scale assessment"News8 min readInconsistent Scale Scoring? Understanding Neuropsychological Scale AssessmentIn neurology, neuropsychological assessment is an indispensable tool in clinical diagnosis and research. However, during clinical scale assessments, raters may apply varying degrees of subjective judgment and interpret the scales inconsistently, leading to differences in scoring outcomes; if a rater uses leading language or questions during the assessment, this can also introduce bias into the results. In the field of neuropsychology in particular, neuropsychological assessment results often serve as the primary endpoint of clinical trials; biased results may reduce a clinical trial's reliability and, in severe cases, lead to study failure. Therefore, standardized training on the use of neuropsychological assessment scales is necessary to...Archived article cover: Committed to serving global clinical research, Microsoft supports EClinCloud's accelerated global expansionNews6 min readCommitted to Serving Global Clinical Research: Microsoft Supports EClinCloud's Accelerated Global ExpansionIn 2015, drug review reform began, and innovation in China's pharmaceutical industry saw explosive growth. With steadily rising R&D investment, innovative drug pipelines expanded rapidly and the number of new drug launches continued to increase. Studies show that over the recent 10-year period (2010–2020), both Investigational New Drug (IND) applications and New Drug Applications (NDAs) in China achieved rapid growth. However, the key metric of "clinical trial phase duration" lengthened from 2572 days to 2688 days. This upward rather than downward trend has made improving clinical trial efficiency one of the most pressing pain points in new drug innovation today. Guided by a core mission centered on digital tools...